ArticleBioactive materials2026
Sulfated polysaccharide facilitates macrophage-Treg crosstalk to mitigate chronic inflammation in diabetic wound healing.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Astaxanthin-metformin conjugate nanomicelles-loaded hydrogel reprograms macrophage metabolismBioactive materials · 2026Article
- Celastrol-Loaded Liposomal Hydrogel Microneedles for Safe and Effective Treatment of Psoriasis.Biomedicines · 2026Article
- Electro-controlled assembled of biphasic guided bone regeneration membrane for healing of diabetic periodontal bone defects.Journal of nanobiotechnology · 2026Article
- FCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy.Journal of translational medicine · 2026Article
- Immunomodulatory roles of regulatory T cells in cutaneous wound healing: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
- Regulatory T Cells in Diabetic Wound Healing: A Comprehensive Review.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds struggle to heal due to chronic inflammation and immune dysregulation, in which regulatory T cells (Tregs) are critical for inflammation resolution and tissue repair. However, effective strategies for on-demand Treg recruitment remain elusive. Here, we innovatively integrated sulfated chitosan (SCS)-a chemically modified polysaccharide-with a microneedle structure to engineer an active immunomodulatory delivery system. The engineered sulfation domains confer synergistic cytokine-binding capacity to SCS, thereby equipping the material with enhanced functionality in immunomodulation. Mechanistically, SCS drives macrophage polarization via the IL-4/STAT6-PPARγ cascade, triggering CCL22-dependent Treg chemotaxis. The SCS establishes bidirectional macrophage-Treg crosstalk, enabling self-sustaining inflammation resolution through M2 phenotype stabilization and Treg-mediated feedback loops. This biomaterial-driven coordination between innate and adaptive immunity surpasses passive drug delivery approaches, effectively reducing inflammation and promoting wound healing without the need for exogenous biologics. Our work pioneers endogenous immunity harnessing through biomaterial design, offering a paradigm shift for diabetic wound therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.